Application of Topical Immunotherapy in the Treatment of Alopecia Areata: A Review and Update

References

• PausR, SlominskiA, CzarnetzkiBM. Is alopecia areata an autoimmune-response against melanogenesis-related proteins, exposed by abnormal MHC class I expression in the anagen hair bulb? Yale J Biol Med. 1993;66(6):541–554.7716973
   PubMed Web of Science ®Google Scholar
• KhunkhetS, VachiramonV, SuchonwanitP. Trichoscopic clues for diagnosis of alopecia areata and trichotillomania in Asians. Int J Dermatol. 2017;56(2):161–165. doi:10.1111/ijd.1345328074524
   PubMed Web of Science ®Google Scholar
• PrattCH, KingLE Jr, MessengerAG, ChristianoAM, SundbergJP. Alopecia areata. Nat Rev Dis Primers. 2017;3(1):17011. doi:10.1038/nrdp.2017.1128300084
   PubMed Web of Science ®Google Scholar
• KassiraS, KortaDZ, ChapmanLW, DannF. Review of treatment for alopecia totalis and alopecia universalis. Int J Dermatol. 2017;56(8):801–810. doi:10.1111/ijd.1361228378336
   PubMed Web of Science ®Google Scholar
• MacDonald HullSP, WoodML, HutchinsonPE, SladdenM, MessengerAG. British association of Dermatologists’ guidelines for the management of alopecia areata. Br J Dermatol. 2003;149(4):692–699. doi:10.1046/j.1365-2133.2003.05535.x14616359
   PubMed Web of Science ®Google Scholar
• SuchonwanitP, KositkuljornC, MahasaksiriT, LeerunyakulK. A comparison of the efficacy and tolerability of three corticosteroid treatment regimens in patients with alopecia areata. J Dermatolog Treat. 2020. 1–6. doi:10.1080/09546634.2020.1773384.
   Web of Science ®Google Scholar
• TriyangkulsriK, SuchonwanitP. Role of janus kinase inhibitors in the treatment of alopecia areata. Drug Des Devel Ther. 2018;12:2323–2335. doi:10.2147/DDDT.S172638
   PubMed Web of Science ®Google Scholar
• MeephansanJ, ThummakriengkraiJ, PonnikornS, YingmemaW, DeenonpoeR, SuchonwanitP. Efficacy of topical tofacitinib in promoting hair growth in non-scarring alopecia: possible mechanism via VEGF induction. Arch Dermatol Res. 2017;309(9):729–738. doi:10.1007/s00403-017-1777-528884378
   PubMed Web of Science ®Google Scholar
• ChanasumonN, SriphojanartT, SuchonwanitP. Therapeutic potential of bimatoprost for the treatment of eyebrow hypotrichosis. Drug Des Devel Ther. 2018;12:365–372. doi:10.2147/DDDT.S156467
   PubMed Web of Science ®Google Scholar
• SuchonwanitP, ThammaruchaS, LeerunyakulK. Minoxidil and its use in hair disorders: a review. Drug Des Devel Ther. 2019;13:2777–2786. doi:10.2147/DDDT.S214907
   PubMed Web of Science ®Google Scholar
• LiuLY, KingBA, CraiglowBG. Health-related quality of life (HRQoL) among patients with alopecia areata (AA): a systematic review. J Am Acad Dermatol. 2016;75(4):806–812.e803. doi:10.1016/j.jaad.2016.04.03527436156
   PubMed Web of Science ®Google Scholar
• RenczF, GulacsiL, PentekM, WikonkalN, BajiP, BrodszkyV. Alopecia areata and health-related quality of life: a systematic review and meta-analysis. Br J Dermatol. 2016;175(3):561–571. doi:10.1111/bjd.1449726914830
   PubMed Web of Science ®Google Scholar
• RattananukromT, SuchonwanitP. Are drug treatment strategies really effective against alopecia areata? Expert Opin Pharmacother. 2020;22(3):257–260. doi:10.1080/14656566.2020.185472833280456
   PubMed Web of Science ®Google Scholar
• RokhsarCK, ShupackJL, VafaiJJ, WashenikK. Efficacy of topical sensitizers in the treatment of alopecia areata. J Am Acad Dermatol. 1998;39(5):751–761. doi:10.1016/S0190-9622(98)70048-99810892
   PubMed Web of Science ®Google Scholar
• PetukhovaL, DuvicM, HordinskyM, et al. Genome-wide association study in alopecia areata implicates both innate and adaptive immunity. Nature. 2010;466(7302):113–117. doi:10.1038/nature0911420596022
   PubMed Web of Science ®Google Scholar
• GregoriouS, PapafragkakiD, KontochristopoulosG, RallisE, KalogeromitrosD, RigopoulosD. Cytokines and other mediators in alopecia areata. Mediators Inflamm. 2010;2010:928030. doi:10.1155/2010/92803020300578
   PubMed Web of Science ®Google Scholar
• ChristophT, Muller-RoverS, AudringH, et al. The human hair follicle immune system: cellular composition and immune privilege. Br J Dermatol. 2000;142(5):862–873. doi:10.1046/j.1365-2133.2000.03464.x10809841
   PubMed Web of Science ®Google Scholar
• KangH, WuWY, LoBK, et al. Hair follicles from alopecia areata patients exhibit alterations in immune privilege-associated gene expression in advance of hair loss. J Invest Dermatol. 2010;130(11):2677–2680. doi:10.1038/jid.2010.18020613773
   PubMed Web of Science ®Google Scholar
• ArcaE, MusabakU, AkarA, ErbilAH, TastanHB. Interferon-gamma in alopecia areata. Eur J Dermatol. 2004;14(1):33–36.14965793
   PubMed Web of Science ®Google Scholar
• Sato-KawamuraM, AibaS, TagamiH. Strong expression of CD40, CD54 and HLA-DR antigen and lack of evidence for direct cellular cytotoxicity are unique immunohistopathological features in alopecia areata. Arch Dermatol Res. 2003;294(12):536–543. doi:10.1007/s00403-002-0354-712624779
   PubMed Web of Science ®Google Scholar
• LeerunyakulK, SuchonwanitP. Asian hair: a Review of structures, properties, and distinctive disorders. Clin Cosmet Investig Dermatol. 2020;13:309–318. doi:10.2147/CCID.S247390
   PubMed Web of Science ®Google Scholar
• SuchonwanitP, McMichaelAJ. Alopecia in association with malignancy: a Review. Am J Clin Dermatol. 2018;19(6):853–865. doi:10.1007/s40257-018-0378-130088232
   PubMed Web of Science ®Google Scholar
• NatprachaW, SukanjanapongS, ChanprapaphK, SuchonwanitP. Characterization and classification of different female hairline patterns in the Thai population. J Cosmet Dermatol. 2021;20(3):890–896. doi:10.1111/jocd.1364232783356
   PubMed Web of Science ®Google Scholar
• ChanprapaphK, TankunakornJ, SuchonwanitP, RutninS. Dermatologic manifestations, histologic features and disease progression among cutaneous lupus erythematosus subtypes: a prospective observational study in asians. Dermatol Ther (Heidelb). 2021;11(1):131–147. doi:10.1007/s13555-020-00471-y33280074
   PubMed Web of Science ®Google Scholar
• ChanprapaphK, PratumchartN, LimtongP, et al. Dipeptidyl peptidase-4 inhibitor-related bullous pemphigoid: a comparative study of 100 patients with bullous pemphigoid and diabetes mellitus. J Dermatol. 2021. doi:10.1111/1346-8138.15778
   PubMed Web of Science ®Google Scholar
• ChanprapaphK, TubtiengI, PratumchatN, ThadaniponK, RattanakaemakornP, SuchonwanitP. Cutaneous, systemic features and laboratory characteristics of late- versus adult-onset systemic lupus erythematosus in 1006 Thai patients. Lupus. 2021;961203321991920. doi:10.1177/096120332199192033554715
   PubMed Web of Science ®Google Scholar
• RojhirunsakoolS, SuchonwanitP. Parietal scalp is another affected area in female pattern hair loss: an analysis of hair density and hair diameter. Clin Cosmet Investig Dermatol. 2018;11:7–12. doi:10.2147/CCID.S153768
   PubMed Web of Science ®Google Scholar
• PausR, BertoliniM. The role of hair follicle immune privilege collapse in alopecia areata: status and perspectives. J Investig Dermatol Symp Proc. 2013;16(1):S25–27. doi:10.1038/jidsymp.2013.7
   PubMedGoogle Scholar
• TerakiY, ImanishiK, ShioharaT. Cytokines in alopecia areata: contrasting cytokine profiles in localized form and extensive form (alopecia universalis). Acta Derm Venereol. 1996;76(6):421–423. doi:10.2340/00015555764214238982401
   PubMed Web of Science ®Google Scholar
• LeeD, HongSK, ParkSW, et al. Serum levels of IL-18 and sIL-2R in patients with alopecia areata receiving combined therapy with oral cyclosporine and steroids. Exp Dermatol. 2010;19(2):145–147. doi:10.1111/j.1600-0625.2009.00937.x19758343
   PubMed Web of Science ®Google Scholar
• KatagiriK, ArakawaS, HatanoY. In vivo levels of IL-4, IL-10, TGF-beta1 and IFN-gamma mRNA of the peripheral blood mononuclear cells in patients with alopecia areata in comparison to those in patients with atopic dermatitis. Arch Dermatol Res. 2007;298(8):397–401. doi:10.1007/s00403-006-0700-217021766
   PubMed Web of Science ®Google Scholar
• BodemerC, PeuchmaurM, FraitaigS, ChatenoudL, BrousseN, De ProstY. Role of cytotoxic T cells in chronic alopecia areata. J Invest Dermatol. 2000;114(1):112–116. doi:10.1046/j.1523-1747.2000.00828.x10620125
   PubMed Web of Science ®Google Scholar
• KryczekI, WeiS, GongW, et al. Cutting edge: IFN-gamma enables APC to promote memory Th17 and abate Th1 cell development. J Immunol. 2008;181(9):5842–5846. doi:10.4049/jimmunol.181.9.584218941172
   PubMed Web of Science ®Google Scholar
• HoffmannR, WenzelE, HuthA, et al. Cytokine mRNA levels in Alopecia areata before and after treatment with the contact allergen diphenylcyclopropenone. J Invest Dermatol. 1994;103(4):530–533. doi:10.1111/1523-1747.ep123957227930677
   PubMed Web of Science ®Google Scholar
• BarahmaniN, LopezA, BabuD, HernandezM, DonleySE, DuvicM. Serum T helper 1 cytokine levels are greater in patients with alopecia areata regardless of severity or atopy. Clin Exp Dermatol. 2010;35(4):409–416. doi:10.1111/j.1365-2230.2009.03523.x19874320
   PubMed Web of Science ®Google Scholar
• SuchonwanitP, HectorCE, Bin SaifGA, McMichaelAJ. Factors affecting the severity of central centrifugal cicatricial alopecia. Int J Dermatol. 2016;55(6):e338–343. doi:10.1111/ijd.1306126769173
   PubMed Web of Science ®Google Scholar
• ShohatM, MimouniD, Ben-AmitaiD, et al. In vitro cytokine profile in childhood alopecia areata and the immunomodulatory effects of AS-101. Clin Exp Dermatol. 2005;30(4):432–434. doi:10.1111/j.1365-2230.2005.01817.x15953089
   PubMed Web of Science ®Google Scholar
• HarnchoowongS, SuchonwanitP. PPAR-γ agonists and their role in primary cicatricial alopecia. PPAR Res. 2017;2017:2501248. doi:10.1155/2017/250124829333153
   PubMed Web of Science ®Google Scholar
• SuchonwanitP, ChalermrojN, KhunkhetS. Low-level laser therapy for the treatment of androgenetic alopecia in Thai men and women: a 24-week, randomized, double-blind, sham device-controlled trial. Lasers Med Sci. 2019;34(6):1107–1114. doi:10.1007/s10103-018-02699-930569416
   PubMed Web of Science ®Google Scholar
• SuchonwanitP, RojhirunsakoolS, KhunkhetS. A randomized, investigator-blinded, controlled, split-scalp study of the efficacy and safety of a 1550-nm fractional erbium-glass laser, used in combination with topical 5% minoxidil versus 5% minoxidil alone, for the treatment of androgenetic alopecia. Lasers Med Sci. 2019;34(9):1857–1864. doi:10.1007/s10103-019-02783-830982177
   PubMed Web of Science ®Google Scholar
• SuchonwanitP, ThammaruchaS. Eyebrow growth pattern analysis in patients with eyebrow hypotrichosis after receiving topical treatment: a retrospective study. J Cosmet Dermatol. 2020;19(6):1404–1408. doi:10.1111/jocd.1316731541563
   PubMed Web of Science ®Google Scholar
• MessengerAG, McKillopJ, FarrantP, McDonaghAJ, SladdenM. British association of Dermatologists’ guidelines for the management of alopecia areata 2012. Br J Dermatol. 2012;166(5):916–926. doi:10.1111/j.1365-2133.2012.10955.x22524397
   PubMed Web of Science ®Google Scholar
• WisemanMC, ShapiroJ, MacDonaldN, LuiH. Predictive model for immunotherapy of alopecia areata with diphencyprone. Arch Dermatol. 2001;137(8):1063–1068.11493099
   PubMedGoogle Scholar
• SuchonwanitP, IamsumangW, RojhirunsakoolS. Efficacy of topical combination of 0.25% finasteride and 3% minoxidil versus 3% minoxidil solution in female pattern hair Loss: a Randomized, Double-Blind, Controlled Study. Am J Clin Dermatol. 2019;20(1):147–153. doi:10.1007/s40257-018-0387-030206824
   PubMed Web of Science ®Google Scholar
• BuckleyDA, Du VivierAW. The therapeutic use of topical contact sensitizers in benign dermatoses. Br J Dermatol. 2001;145(3):385–405. doi:10.1046/j.1365-2133.2001.04399.x11531828
   PubMed Web of Science ®Google Scholar
• SutherlandL, LaschingerM, SyedZU, GaspariA. Treatment of alopecia areata with topical sensitizers. Dermatitis. 2015;26(1):26–31. doi:10.1097/DER.000000000000009425581667
   PubMed Web of Science ®Google Scholar
• HappleR. Antigenic competition as a therapeutic concept for alopecia areata. Arch Dermatol Res. 1980;267(1):109–114. doi:10.1007/BF004169316446265
   PubMed Web of Science ®Google Scholar
• ZollerM, Freyschmidt-PaulP, VitacolonnaM, McElweeKJ, HummelS, HoffmannR. Chronic delayed-type hypersensitivity reaction as a means to treat alopecia areata. Clin Exp Immunol. 2004;135(3):398–408. doi:10.1111/j.1365-2249.2003.02380.x15008971
   PubMed Web of Science ®Google Scholar
• HerbstV, ZollerM, KisslingS, WenzelE, StutzN, Freyschmidt-PaulP. Diphenylcyclopropenone treatment of alopecia areata induces apoptosis of perifollicular lymphocytes. Eur J Dermatol. 2006;16(5):537–542.17101475
   PubMed Web of Science ®Google Scholar
• KuwanoY, FujimotoM, WatanabeR, et al. Serum chemokine profiles in patients with alopecia areata. Br J Dermatol. 2007;157(3):466–473. doi:10.1111/j.1365-2133.2007.07943.x17489976
   PubMed Web of Science ®Google Scholar
• GulatiN, Suarez-FarinasM, Fuentes-DuculanJ, et al. Molecular characterization of human skin response to diphencyprone at peak and resolution phases: therapeutic insights. J Invest Dermatol. 2014;134(10):2531–2540. doi:10.1038/jid.2014.19624751728
   PubMed Web of Science ®Google Scholar
• ZollerM, McElweeKJ, VitacolonnaM, HoffmannR. The progressive state, in contrast to the stable or regressive state of alopecia areata, is reflected in peripheral blood mononuclear cells. Exp Dermatol. 2004;13(7):435–444. doi:10.1111/j.0906-6705.2004.00179.x15217364
   PubMed Web of Science ®Google Scholar
• ManimaranRP, RamassamyS, RajappaM, ChandrashekarL. Therapeutic outcome of diphencyprone and its correlation with serum cytokine profile in alopecia areata. J Dermatolog Treat. 2020;1–5. doi:10.1080/09546634.2020.1752887
   Web of Science ®Google Scholar
• KonigA, HappleR, HoffmannR. IFN-gamma-induced HLA-DR but not ICAM-1 expression on cultured dermal papilla cells is downregulated by TNF-alpha. Arch Dermatol Res. 1997;289(8):466–470. doi:10.1007/s0040300502229266024
   PubMed Web of Science ®Google Scholar
• LeeSH, MoonJH, BanDH, ByunJW, ShinJ, ChoiGS. Can the cytokine analysis of the scales on alopecic patch predict the response to diphenylcyclopropenone treatment in Alopecia Areata patients? Ann Dermatol. 2018;30(2):150–157. doi:10.5021/ad.2018.30.2.15029606811
   PubMed Web of Science ®Google Scholar
• GongY, ZhaoY, ZhangX, et al. Serum level of IL-4 predicts response to topical immunotherapy with diphenylcyclopropenone in alopecia areata. Exp Dermatol. 2020;29(3):231–238. doi:10.1111/exd.1375830047620
   PubMed Web of Science ®Google Scholar
• StuteJ, HausenBM, SchulzKH. [Diphenylcyclopropenone - a new strong contact sensitizer]. Derm Beruf Umwelt. 1981;29(1):12–14. German.6452255
   PubMedGoogle Scholar
• StrazzullaLC, WangEHC, AvilaL, et al. Alopecia areata: an appraisal of new treatment approaches and overview of current therapies. J Am Acad Dermatol. 2018;78(1):15–24. doi:10.1016/j.jaad.2017.04.114229241773
   PubMed Web of Science ®Google Scholar
• HigginsE, Du VivierA. Topical immunotherapy: unapproved uses, dosages, or indications. Clin Dermatol. 2002;20(5):515–521. doi:10.1016/S0738-081X(02)00272-912435522
   PubMed Web of Science ®Google Scholar
• BlackHS, CastrowFF 2nd, GerguisJ. The mutagenicity of dinitrochlorobenzene. Arch Dermatol. 1985;121(3):348–349. doi:10.1001/archderm.1985.016600300700213883905
   PubMedGoogle Scholar
• BreuillardF, SzapiroE. Dinitrochlorobenzene in alopecia areata. Lancet. 1978;312(8103):1304. doi:10.1016/S0140-6736(78)92059-7
   Google Scholar
• FriedmannPS. Response of alopecia areata to DNCB: influence of auto-antibodies and route of sensitization. Br J Dermatol. 1981;105(3):285–289. doi:10.1111/j.1365-2133.1981.tb01287.x7272208
   PubMed Web of Science ®Google Scholar
• SwansonNA, MitchellAJ, LeahyMS, HeadingtonJT, DiazLA. Topical treatment of alopecia areata. Arch Dermatol. 1981;117(7):384–387. doi:10.1001/archderm.1981.016500700120117259216
   PubMedGoogle Scholar
• SinglaA, MittalRR, WaliaRLS, BansalIJS. Comparative efficacy of topical DNCB and PUVASOL therapy in alopecia areata. Indian J Dermatol Venereol Leprol. 1991;57.
   Google Scholar
• YoshizawaY, IzakiS, KitamuraK, KawanaS. Systemic immunotherapy with topical dinitrochlorobenzene as additional treatment of alopecia areata. Acta Derm Venereol. 2002;82(2):136–138. doi:10.1080/0001555025294820212125944
   PubMed Web of Science ®Google Scholar
• HappleR, KalveramKJ, BüchnerU, Echternacht-HappleK, GöggelmannW, SummerKH. Contact allergy as a therapeutic tool for alopecia areata: application of squaric acid dibutylester. Dermatologica. 1980;161(5):289–297. doi:10.1159/0002503807439477
   PubMedGoogle Scholar
• WilkersonMG, HenkinJ, WilkinJK, SmithRG. Squaric acid and esters: analysis for contaminants and stability in solvents. J Am Acad Dermatol. 1985;13(2):229–234. doi:10.1016/S0190-9622(85)70164-84044949
   PubMed Web of Science ®Google Scholar
• LeeS, KimBJ, LeeYB, LeeWS. Hair regrowth outcomes of contact immunotherapy for patients with Alopecia Areata: a systematic review and meta-analysis. JAMA Dermatol. 2018;154(10):1145–1151. doi:10.1001/jamadermatol.2018.231230073292
   PubMed Web of Science ®Google Scholar
• GuptaAK, CarvielJL, FoleyKA, et al. Monotherapy for Alopecia Areata: a systematic Review and network meta-analysis. Skin Appendage Disord. 2019;5(6):331–337. doi:10.1159/00050194031799258
   PubMed Web of Science ®Google Scholar
• TostiA, CaponeriGM, PrimativoR, MelinoM, VeronesiS. Squaric acid dibutyl ester and diphencyprone in the therapy of alopecia areata. G Ital Dermatol Venereol. 1985;120(5):371–373.4077112
   PubMedGoogle Scholar
• MicaliG, CiceroRL, NascaMR, SapuppoA. Treatment of alopecia areata with squaric acid dibutylester. Int J Dermatol. 1996;35(1):52–56. doi:10.1111/j.1365-4362.1996.tb01618.x8838932
   PubMed Web of Science ®Google Scholar
• Dall’oglioF, NascaMR, MusumeciML, et al. Topical immunomodulator therapy with squaric acid dibutylester (SADBE) is effective treatment for severe alopecia areata (AA): results of an open-label, paired-comparison, clinical trial. J Dermatolog Treat. 2005;16(1):10–14. doi:10.1080/0954663041002360115897160
   PubMed Web of Science ®Google Scholar
• ChuaSH, GohCL, AngCB. Topical squaric acid dibutylester therapy for alopecia areata: a double-sided patient-controlled study. Ann Acad Med Singapore. 1996;25(6):842–847.9055014
   PubMedGoogle Scholar
• CaserioRJ. Treatment of alopecia areata with squaric acid dibutylester. Arch Dermatol. 1987;123(8):1036–1041. doi:10.1001/archderm.1987.016603200780163307636
   PubMedGoogle Scholar
• GiannettiA, OrecchiaG. Clinical experience on the treatment of alopecia areata with squaric acid dibutyl ester. Dermatologica. 1983;167(5):280–282. doi:10.1159/0002497976653853
   PubMedGoogle Scholar
• TostiA, De PadovaMP, MinghettiG, VeronesiS. Therapies versus placebo in the treatment of patchy alopecia areata. J Am Acad Dermatol. 1986;15(2):209–210. doi:10.1016/S0190-9622(86)70158-83528241
   PubMed Web of Science ®Google Scholar
• JohanssonE, RankiA, ReunalaT, KiantoU, NiemiKM. Immunohistological evaluation of alopecia areata treated with squaric acid dibutylester (SADBE). Acta Derm Venereol. 1986;66(6):485–490.2433867
   PubMed Web of Science ®Google Scholar
• OrecchiaG, RabbiosiG. Patterns of hair regrowth in alopecia areata. Dermatologica. 1988;176(5):270–272. doi:10.1159/0002487183384153
   PubMedGoogle Scholar
• OrecchiaG, MalagoliP, SantagostinoL. Treatment of severe alopecia areata with squaric acid dibutylester in pediatric patients. Pediatr Dermatol. 1994;11(1):65–68. doi:10.1111/j.1525-1470.1994.tb00078.x8170854
   PubMed Web of Science ®Google Scholar
• TostiA, GuidettiMS, BardazziF, MiscialiC. Long-term results of topical immunotherapy in children with alopecia totalis or alopecia universalis. J Am Acad Dermatol. 1996;35(2):199–201. doi:10.1016/S0190-9622(96)90323-08708020
   PubMed Web of Science ®Google Scholar
• IijimaS, OtsukaF. Prognostic factors for clinical response of Alopecia Areata to topical immunotherapy with squaric acid dibutylester. Arch Dermatol. 1997;133(4):539–540. doi:10.1001/archderm.133.4.5399126022
   PubMedGoogle Scholar
• SakaiK, FukushimaS, MizuhashiS, et al. Effect of topical immunotherapy with squaric acid dibutylester for alopecia areata in Japanese patients. Allergol Int. 2019;69(2):274–278. doi:10.1016/j.alit.2019.10.00831767273
   PubMed Web of Science ®Google Scholar
• ChenCA, CarlbergV, KroshinskyD. angioedema after squaric acid treatment in a 6-year-old girl. Pediatr Dermatol. 2017;34(1):e44–e46. doi:10.1111/pde.1299327699860
   PubMed Web of Science ®Google Scholar
• NascaMR, CiceroRL, InnocenziD, MicaliG. Persistent allergic contact dermatitis at the site of primary sensitization with squaric acid dibutyl ester. Contact Dermatitis. 1995;33(6):438. doi:10.1111/j.1600-0536.1995.tb02090.x8706413
   PubMed Web of Science ®Google Scholar
• TodaroA, NavaC. Allergic disease caused by squaric acid dibutyl ester: description of 2 cases in a work environment. Med Lav. 1991;82(3):276–279.1795673
   PubMedGoogle Scholar
• UjiieH, SawamuraD, ShibakiA, ShimizuH. Prolonged dermatitis distant to the site of squaric acid dibutyl ester applications and recovery of alopecia areata. Clin Exp Dermatol. 2005;30(5):579–580. doi:10.1111/j.1365-2230.2005.01804.x16045698
   PubMed Web of Science ®Google Scholar
• ValsecchiR, PanseraB, RossiA, CainelliT. Pigmentation abnormalities in the course of topical immunotherapy of alopecia areata. G Ital Dermatol Venereol. 1989;124(1–2):31–32.2527809
   PubMedGoogle Scholar
• ValsecchiR, CainelliT. Depigmentation from squaric acid dibutylester. Contact Dermatitis. 1984;10(2):109. doi:10.1111/j.1600-0536.1984.tb00349.x6232090
   PubMed Web of Science ®Google Scholar
• HappleR, HausenBM, Wiesner-MenzelL. Diphencyprone in the treatment of alopecia areata. Acta Derm Venereol. 1983;63(1):49–52.6191489
   PubMed Web of Science ®Google Scholar
• BorowskaK, WasylyszynT. Stability of solutions of 2,3-diphenylcyclopropenone in various solvents. A novel formula - diphenylcyclopropenone in isopropanol may be useful in topical therapy of patients with Alopecia Areata. Acta Pol Pharm. 2017;74(2):459–464.29624251
   PubMed Web of Science ®Google Scholar
• JangYH, JungHJ, MoonSY, et al. Systematic review and quality analysis of studies on the efficacy of topical diphenylcyclopropenone treatment for alopecia areata. J Am Acad Dermatol. 2017;77(1):170–172. doi:10.1016/j.jaad.2017.03.01528619558
   PubMed Web of Science ®Google Scholar
• NasimiM, AbediniR, GhandiN, SeirafiH, Sadat MehdizadeM, TootoonchiN. Topical immunotherapy with diphenylcyclopropenone in patients with alopecia areata: a large retrospective study of 757 patients. Dermatol Ther. 2020;33(6):e13808. doi:10.1111/dth.1380832530566
   PubMed Web of Science ®Google Scholar
• HullSM, PepallL, CunliffeWJ. Alopecia areata in children: response to treatment with diphencyprone. Br J Dermatol. 1991;125(2):164–168. doi:10.1111/j.1365-2133.1991.tb06064.x1911299
   PubMed Web of Science ®Google Scholar
• SalsbergJM, DonovanJ. The safety and efficacy of diphencyprone for the treatment of alopecia areata in children. Arch Dermatol. 2012;148(9):1084–1085. doi:10.1001/archdermatol.2012.162222986874
   PubMedGoogle Scholar
• ChoeSJ, LeeS, LeeH, ChoiJ, LeeWS. Efficacy of topical diphenylcyclopropenone maintenance treatment for patients with alopecia areata: a retrospective study. J Am Acad Dermatol. 2018;78(1):205–207 e201. doi:10.1016/j.jaad.2017.07.02829241788
   PubMed Web of Science ®Google Scholar
• HullSM, CunliffeWJ. Post-therapy relapse rate in alopecia areata after successful treatment with diphencyprone. J Dermatolog Treat. 1989;1(2):71–74.
   Google Scholar
• van der SteenPH, BoezemanJB, HappleR. Topical immunotherapy for alopecia areata: re-evaluation of 139 cases after an additional follow-up period of 19 months. Dermatology. 1992;184(3):198–201. doi:10.1159/0002475401392112
   PubMed Web of Science ®Google Scholar
• HullSM, NorrisJF. Diphencyprone in the treatment of long-standing alopecia areata. Br J Dermatol. 1988;119(3):367–374. doi:10.1111/j.1365-2133.1988.tb03230.x3052565
   PubMed Web of Science ®Google Scholar
• HatzisJ, GeorgiotouoK, KostakisP, et al. Treatment of alopecia areata with diphencyprone. Australas J Dermatol. 1988;29(1):33–36. doi:10.1111/j.1440-0960.1988.tb01223.x2977943
   PubMedGoogle Scholar
• MonkB. Induction of hair growth in alopecia totalis with diphencyprone sensitization. Clin Exp Dermatol. 1989;14(2):154–157. doi:10.1111/j.1365-2230.1989.tb00915.x2598490
   PubMed Web of Science ®Google Scholar
• AshworthJ, TuypE, MackieRM. Allergic and irritant contact dermatitis compared in the treatment of alopecia totalis and universalis. A comparison of the value of topical diphencyprone and tretinoin gel. Br J Dermatol. 1989;120(3):397–401. doi:10.1111/j.1365-2133.1989.tb04166.x2713259
   PubMed Web of Science ®Google Scholar
• HullSM, CunliffeWJ. Successful treatment of alopecia areata using the contact allergen diphencyprone. Br J Dermatol. 1991;124(2):212–213. doi:10.1111/j.1365-2133.1991.tb00443.x
   PubMed Web of Science ®Google Scholar
• van der SteenPH, van BaarHM, PerretCM, HappleR. Treatment of alopecia areata with diphenylcyclopropenone. J Am Acad Dermatol. 1991;24(2):253–257. doi:10.1016/0190-9622(91)70037-32007671
   PubMed Web of Science ®Google Scholar
• HotingE, BoehmA. Therapy of alopecia areata with diphencyprone. Br J Dermatol. 1992;127(6):625–629. doi:10.1111/j.1365-2133.1992.tb14877.x1476922
   PubMed Web of Science ®Google Scholar
• GordonPM, AldrigeRD, McVittieE, HunterJA. Topical diphencyprone for alopecia areata: evaluation of 48 cases after 30 months’ follow-up. Br J Dermatol. 1996;134(5):869–871. doi:10.1111/j.1365-2133.1996.tb06317.x8736327
   PubMed Web of Science ®Google Scholar
• SchuttelaarML, HamstraJJ, PlinckEP, et al. Alopecia areata in children: treatment with diphencyprone. Br J Dermatol. 1996;135(4):581–585. doi:10.1111/j.1365-2133.1996.tb03835.x8915150
   PubMed Web of Science ®Google Scholar
• PericinM, TruebRM. Topical immunotherapy of severe alopecia areata with diphenylcyclopropenone: evaluation of 68 cases. Dermatology. 1998;196(4):418–421. doi:10.1159/0000179359669118
   PubMed Web of Science ®Google Scholar
• CotellessaC, PerisK, CaraccioloE, MordentiC, ChimentiS. The use of topical diphenylcyclopropenone for the treatment of extensive alopecia areata. J Am Acad Dermatol. 2001;44(1):73–76. doi:10.1067/mjd.2001.10930911148480
   PubMed Web of Science ®Google Scholar
• AghaeiS. Topical immunotherapy of severe alopecia areata with diphenylcyclopropenone (DPCP): experience in an Iranian population. BMC Dermatol. 2005;5(1):6. doi:10.1186/1471-5945-5-615918897
   PubMedGoogle Scholar
• AvgerinouG, GregoriouS, RigopoulosD, StratigosA, KalogeromitrosD, KatsambasA. Alopecia areata: topical immunotherapy treatment with diphencyprone. J Eur Acad Dermatol Venereol. 2008;22(3):320–323. doi:10.1111/j.1468-3083.2007.02411.x18005118
   PubMed Web of Science ®Google Scholar
• OhlmeierMC, TraupeH, LugerTA, BohmM. Topical immunotherapy with diphenylcyclopropenone of patients with alopecia areata–a large retrospective study on 142 patients with a self-controlled design. J Eur Acad Dermatol Venereol. 2012;26(4):503–507. doi:10.1111/j.1468-3083.2011.04114.x21569118
   PubMed Web of Science ®Google Scholar
• PanR, LiuJ, XuanX, LiB. Chinese experience in the treatment of alopecia areata with diphenylcyclopropenone. J Dermatol. 2015;42(2):220–221. doi:10.1111/1346-8138.1274325545114
   PubMed Web of Science ®Google Scholar
• ChiangKS, MesinkovskaNA, PiliangMP, BergfeldWF. Clinical efficacy of diphenylcyclopropenone in Alopecia Areata: retrospective data analysis of 50 patients. J Investig Dermatol Symp Proc. 2015;17(2):50–55. doi:10.1038/jidsymp.2015.28
   PubMedGoogle Scholar
• LambRC, YoungD, HolmesS. Retrospective review of diphencyprone in the treatment of alopecia areata. Clin Exp Dermatol. 2016;41(4):352–358. doi:10.1111/ced.1277626620737
   PubMed Web of Science ®Google Scholar
• DurduM, OzcanD, BabaM, SeckinD. Efficacy and safety of diphenylcyclopropenone alone or in combination with anthralin in the treatment of chronic extensive alopecia areata: a retrospective case series. J Am Acad Dermatol. 2015;72(4):640–650. doi:10.1016/j.jaad.2015.01.00825653027
   PubMed Web of Science ®Google Scholar
• IbrahimSA, EsawyAM, AbdelshafyAS. Treatment of chronic extensive alopecia areata by diphenylcyclopropenone alone versus in combination with anthralin. Dermatol Ther. 2019;32(5):e13010. doi:10.1111/dth.1301031237076
   PubMed Web of Science ®Google Scholar
• KagamiS, KishiY, HinoH. Topical immunotherapy in combination with anthralin in the treatment of refractory alopecia areata. J Cosmet Dermatol. 2020;19(9):2411–2414. doi:10.1111/jocd.1358832621407
   PubMed Web of Science ®Google Scholar
• NasimiM, GhandiN, AbediniR, MirshamsiA, ShakoeiS, SeirafiH. Efficacy and safety of anthralin in combination with diphenylcyclopropenone in the treatment of alopecia areata: a retrospective case series. Arch Dermatol Res. 2019;311(8):607–613. doi:10.1007/s00403-019-01940-x31165933
   PubMed Web of Science ®Google Scholar
• ShapiroJ, TanJ, HoV, AbbottF, TronV. Treatment of chronic severe alopecia areata with topical diphenylcyclopropenone and 5% minoxidil: a clinical and immunopathologic evaluation. J Am Acad Dermatol. 1993;29(5):729–735. doi:10.1016/0190-9622(93)70238-O7901248
   PubMed Web of Science ®Google Scholar
• WasylyszynT, BorowskaK. Possible advantage of imiquimod and diphenylcyclopropenone combined treatment versus diphenylcyclopropenone alone: an observational study of nonresponder patients with alopecia areata. Australas J Dermatol. 2017;58(3):219–223. doi:10.1111/ajd.1247827087586
   PubMed Web of Science ®Google Scholar
• SriphojanartT, KhunkhetS, SuchonwanitP. A retrospective comparative study of the efficacy and safety of two regimens of diphenylcyclopropenone in the treatment of recalcitrant alopecia areata. Dermatol Reports. 2017;9(2):7399. doi:10.4081/dr.2017.739929299216
   PubMed Web of Science ®Google Scholar
• ThuangtongR, VarothaiS, TriwongwaranatD, RujitharanawongC. Multi-concentration level patch test guided Diphenyl Cyclopropenone (DPCP) treatment in alopecia totalis or alopecia universalis. J Med Assoc Thai. 2017;100(1):86–92.29911776
   PubMedGoogle Scholar
• NowickaD, MajJ, Jankowska-KonsurA, Hryncewicz-GwozdzA. Efficacy of diphenylcyclopropenone in alopecia areata: a comparison of two treatment regimens. Postepy Dermatol Alergol. 2018;35(6):577–581. doi:10.5114/ada.2018.7760830618524
   PubMed Web of Science ®Google Scholar
• LeeS, LeeWS. Home-based contact immunotherapy with diphenylcyclopropenone for alopecia areata is as effective and safe as clinic-based treatment in patients with stable disease: a retrospective study of 40 patients. J Am Acad Dermatol. 2018;78(3):599–601.e591. doi:10.1016/j.jaad.2017.09.03728947296
   PubMed Web of Science ®Google Scholar
• KimBJ, LeeS, LeeCH, LeeWS. Home-based contact immunotherapy with diphenylcyclopropenone improves compliance with the recommended follow-up for patients with alopecia areata: a retrospective cohort study. J Am Acad Dermatol. 2020;82(5):1223–1225. doi:10.1016/j.jaad.2019.10.04331678469
   PubMed Web of Science ®Google Scholar
• FrancomanoM, SeidenariS. Urticaria after topical immunotherapy with diphenylcyclopropenone. Contact Dermatitis. 2002;47(5):310–311. doi:10.1034/j.1600-0536.2002.4705102.x12534538
   PubMed Web of Science ®Google Scholar
• SharmaVK, MuralidharS. Topical immunotherapy with diphencyprone in Indians with alopecia areata. Clin Exp Dermatol. 1998;23(6):291–292. doi:10.1046/j.1365-2230.1998.00254.x10233630
   PubMed Web of Science ®Google Scholar
• SangerJ, ZahirA, DriscollM, GaspariAA. Erythema multiforme major after immunotherapy with diphenylcyclopropenone for Alopecia Areata. Dermatitis. 2018;29(6):348–349. doi:10.1097/DER.000000000000041530346328
   PubMed Web of Science ®Google Scholar
• BuchananR, HuynhG, TannerJ. Extensive scalp angioedema following high-dose diphenylcyclopropenone for alopecia areata. Hosp Pharm. 2014;49(1):48–51. doi:10.1310/hpj4901-4824421563
   PubMedGoogle Scholar